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Introduction: GATA2 was recently described as a critical survival 
factor and therapeutic target for KRAS mutant non–small-cell lung 
cancer (NSCLC). However, whether this role is affected by epigen-
etic repression of GATA2 in lung cancer is unclear.
Methods: GATA2 expression and promoter CpG island meth-
ylation were evaluated using human and mouse NSCLC cell lines 
and  tumor-normal pairs. In vitro assays were used to study GATA2 
repression on cell survival and during tobacco carcinogen-induced 
transformation.
Results: GATA2 expression in KRAS wild-type (n = 15) and mutant 
(n = 10) NSCLC cell lines and primary lung tumors (n = 24) was sig-
nificantly lower, 1.3- to 33.6-fold (p = 2.2 × 109), compared with corre-
sponding normal lung. GATA2 promoter was unmethylated in normal 
lung (0 of 10) but frequently methylated in lung tumors (96%, 159 
of 165) and NSCLC cell lines (97%, 30 of 31). This highly prevalent 
aberrant methylation was independently validated using The Cancer 
Genome Atlas data for 369 NSCLC  tumor-normal pairs. In vitro stud-
ies using an established carcinogen-induced premalignancy model 
revealed that GATA2 expression was initially repressed by chromatin 
remodeling followed by cytosine methylation during transformation. 
Similarly, expression of GATA2 in  NNK-induced mouse lung tumors 
(n = 6) and cell lines (n = 5) was fivefold and  100-fold lower, respec-
tively, than normal mouse lung. Finally, siRNA-mediated knockdown 
of GATA2 in KRAS mutant (human [n = 4] and murine [n = 5]) and 
wild-type (human [n = 4]) NSCLC cell lines showed that further reduc-
tion of expression (up to 95%) does not induce cell death.
Conclusion: GATA2 is epigenetically repressed in human and mouse 
lung tumors and its further inhibition is not a valid therapeutic strat-
egy for KRAS mutant lung cancer.
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(J Thorac Oncol. 2014;9: 784–793)
Lung cancer remains the most common and the leading cause of cancer mortality worldwide with approximately 
1.6 million new cases and 1.4 million deaths a year.1 Currently, 
there is no established screening protocol for lung cancer, thus 
most patients are diagnosed at an advanced stage of the dis-
ease with poor prognosis.2 Lung tumors in approximately 50% 
of patients are driven by specific mutations to genes such as 
KRAS (20–30%), EGFR (10–20%), BRAF (<5%), PIK3CA 
(<5%), and EML4-ALK translocation (5–15%).3 Targeted 
inhibition of these key cancer-driver mutations for the treat-
ment of lung cancer has produced encouraging results leading 
to a growing optimism that personalized therapy could sig-
nificantly improve treatment responses and patients’ survival. 
Drugs targeting the EGFR pathway (e.g., gefitinib, erlotinib) 
have already been approved for frontline therapy of EGFR 
mutant lung tumors and have dramatically improved the 
response rate.4–6 Clinical trials using inhibitors of ALK, PI3K, 
BRAF, HER2, and AKT are currently underway.7–12 However, 
targeting the RAS family of oncogenes, the most common 
cancer-driver mutations in lung cancer, has not been success-
ful. Kumar et al.13 recently took a different approach to indi-
rectly target these oncogenes and showed that KRAS mutant 
lung tumors depend on GATA2 expression for survival.
GATA2 is a member of the GATA family of zinc finger 
proteins that serves as a transcriptional activator or repressor 
of multiple genes regulating diverse cellular processes dur-
ing development and carcinogenesis. Six genes (GATA1–6) 
constitute the GATA family in human. GATA1 to GATA3 are 
expressed mainly in the hematopoietic cell lineage, whereas 
GATA4 to GATA6 are found in many organs including the 
heart, lung, liver, gastrointestinal tract and are implicated in 
regulating epithelial cell differentiation.14 GATA2 is consid-
ered the master regulator of hematopoietic stem cells and pro-
genitor cells and its role during development and malignancy 
of the hematopoietic system has been well established.15,16 It 
is abundantly expressed and indispensable for the prolifera-
tion, maintenance, and function of hematopoietic stem cells 
and progenitor cells.17–19 GATA2 expression decreases dur-
ing hematopoietic stem cells/progenitor cells differentiation, 
and its downregulation is key for terminal differentiation.20 
GATA2 null mice show defective hematopoiesis and die of 
anemia at days 10 to 11 of gestation.18 Overexpression and 
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mutations of GATA2 have been demonstrated in myelodys-
plastic syndrome, acute, and chronic myeloid leukemia.21–23 In 
contrast, the level of GATA2 expression and its role in normal 
lung and during lung carcinogenesis is unclear.
Epigenetic regulation of the GATA family genes through 
promoter CpG island methylation has been demonstrated for 
GATA4 and GATA5 in lung, colorectal, gastric, and ovarian can-
cers.24,25 Our previous transcriptome array-based  genome-wide 
screen for epigenetically silenced genes in non–small-cell lung 
cancer (NSCLC) cell lines identified GATA2 as one of the 
repressed genes.26 Similarly, our study using cumene-induced 
lung tumors in B6C3F1 mice also showed that Gata2 was epi-
genetically repressed. However, the promoter CpG island of 
Gata2 was not methylated in the mouse tumors indicating other 
epigenetic changes such as chromatin modifications could be 
responsible for Gata2 repression.27 Given the recent excitement 
about targeting GATA2 for the treatment of KRAS mutant lung 
cancer,13 we further characterized the role of epigenetic regula-
tion of GATA2 during lung carcinogenesis and its impact on 
the survival of KRAS mutant lung cancer.
The objective of this study was to answer the following 
key questions. (1) Does epigenetic regulation of GATA2 in 
lung cancer differ by KRAS mutation status? (2) Why would 
a gene critically required for the survival of KRAS mutant 
lung cancer cells be epigenetically repressed in lung cancer? 
Since the study by Kumar et al.13 did not evaluate GATA2 in 
lung cancer patients, we first determined the level of GATA2 
expression in lung tumor-normal pairs and compared it with 
KRAS mutant and wild-type NSCLC cell lines. Methylation 
of the GATA2 promoter CpG island was evaluated in lung 
tumor-normal pairs and NSCLC cell lines, and the results 
were validated using publicly available methylation data for 
lung tumor-normal pairs from The Cancer Genome Atlas 
(TCGA) project. The timing for aberrant epigenetic changes 
of GATA2 during early lung carcinogenesis was established 
using the in vitro transformation model developed in our lab-
oratory.28,29 Expression and methylation of the mouse Gata2 
gene was also evaluated using normal lung and 4-methylni-
trosamino-1-(3-pyridyl)-1-butanone (NNK)-induced lung 
tumors in A/J mice and mouse NSCLC cell lines derived 
from these tumors. Finally, the impact of siRNA-mediated 
knockdown of GATA2 on the survival of KRAS wild-type 
and mutant lung cancer cells was investigated using human 
and mouse NSCLC cell lines.
MATERIALS AND METHODS
Tissue Samples and Cell Lines
Lung tumor-normal pairs from 165 adenocarcinoma 
patients were obtained from frozen tumor banks at University 
of New Mexico and Johns Hopkins. Additional lung tumor-
normal pairs from an independent group of 56 NSCLC patients 
were obtained from the Mayo Clinic. Normal human bron-
chial epithelial cells collected through diagnostic bronchos-
copy30 and peripheral blood mononuclear cells were obtained 
from cancer-free smokers (University of New Mexico). All 
samples were obtained with written informed consent from 
patients, and the study was approved by the institute’s Ethics 
Committee. Five human bronchial epithelial cell (HBEC) lines 
(HBEC1, 2, 3, 13, and 14) immortalized as described31 were 
obtained from Drs Shay and Minna, Southwestern Medical 
Center, Dallas, TX. NSCLC cell lines obtained from and 
authenticated by the American Type Culture Collection were 
used. This include H23, H358, H441, H1435, H1568, H1734, 
H1993, H2009, H2023, H2085, H2228, Calu-3, Calu-6, 
SKLU1, A549, H1650, H1838, H1975, HCC827, HCC4006, 
H3255, PC9, SW900, SKMES1, H520, H522, H2170, H460, 
H1299, H1869, and H1770. Experiments were conducted in 
cell lines passed for a maximum of 6 months post-resusci-
tation. Normal lung tissues, NNK-induced lung tumors and 
lung adenocarcinomas cell lines (IO33, CL13, CL20, CL25, 
and CL30) derived from NNK-induced lung tumors all from 
A/J mice were obtained from previously described study.32,33
Carcinogens Exposures and Epigenetic  
Drug Treatments
HBECs exposed to the tobacco carcinogens methylnitro-
sourea and benzo(a)pyrene-diolepoxide for 4 to 12 weeks and 
transformed HBECs selected for growth in soft agar after 12 
weeks exposure were obtained from previous experiments.28,29 
Cell lines were treated with vehicle (0.6 μl ethanol in 10 ml 
medium), the class I and II histone deacetylase inhibitor tricho-
statin A (TSA; 300 nM for 18 [ours [Sigma; stock solution 
5 mM in ethanol]), or the DNA methyltransferases inhibitor 
5-Aza-2’-deoxycytidine (DAC; 500 nM every 12 hours for 96 
hours [Sigma; stock solution 100 mM in phosphate-buffered 
saline]) as described.34
DNA Methylation and Gene Expression Analysis
Combined Bisulfite Modification and Restriction 
Analysis and Methylation-Specific polymerase chain reac-
tion (MSP) assays were performed as described35 to evaluate 
GATA2 methylation in lung tumors (n = 165) and distant nor-
mal lung tissue (n = 10) from the adenocarcinoma patients, 
normal human bronchial epithelial cells (n = 10), HBEC 
(n = 5), peripheral blood mononuclear cells (n = 10), and 
NSCLC cell lines (n = 31). Primer sequences and ampli-
fication conditions are described in supporting Table 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A556). Lung tumors (n = 56) and distant normal lung tissue 
pairs (n = 21) from the independent group of 56 NSCLC cases 
were used for quantitative methylation analysis using the 
Infinium HumanMethylation450 beadchip (HM450K) from 
Illumina (San Diego, CA) as recommended.36 The TCGA 
HM450K data were obtained from  http://genome.ucsc.edu/
cgi-bin/hgTracks?hgsid=311019695.
Gene expression analysis was performed for 24 lung 
tumor-normal pairs from the adenocarcinoma cases and 
NSCLC and control cell lines using SYBR Green (for primers 
and amplification conditions see Table 1 [Supplemental Digital 
Content 1, http://links.lww.com/JTO/A556]) and TaqMan 
assays as described.37–39 For human gene expression analysis, 
TaqMan assays for GATA2 all transcripts (Hs00231119_m1), 
Var2 (Hs00925057_m1), Var1 and 2 (Hs00925060_m1), 
Var1 and 3 (Hs00927739_m1), Var3 (Hs00927741_m1), and 
the housekeeping gene BETA-ACTIN (4310881E) all from 
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Applied Biosystems were used. Expressions in the mouse 
samples were evaluated using TaqMan assays (Applied 
Biosystems) for Gata2 (Mm00492301), β-actin (4352341E), 
and Gapdh (4352339E). All samples were analyzed at least 
twice in duplicate and relative expression levels were calcu-
lated using ΔΔCT method as described.40
GATA2 Knockdown and Cell Death Assays
Cells were transfected with siControl (negative con-
trol #1) or GATA2 specific human (siGATA2-#1 [s5598], 
siGATA2-#2 [s5597]) or mouse (siGata2-#1 [s66477], 
siGata2-#2 [s66478]) siRNAs (each at 20 pmol concen-
tration) from Applied Biosystems (Foster City, CA) using 
Lipofectamine 2000 (Invitrogen, Santa Clara, CA) as 
described.39 Live and dead cells were counted by trypan blue 
viability assay using the Countess automated cell counter 
(Invitrogen) and gene expression was evaluated as above. 
Each experiment was conducted in triplicate and cell survival 
was determined as a percentage to the total cell count.
Immunoblotting
Human and mouse NSCLC cell lines without or 72 
hour post-siRNA transfection were washed with ice-cold, 
 phosphate-buffered saline and lysed with RIPA Lysis Buffer con-
taining 50 mM Tris pH8, 1% Np-40, 1 M NaCl, 1 mM ethylene-
diaminetetraacetic acid (EDTA), and 0.25% Na-deoxycholate 
and a 1× cocktail of protease inhibitors (Sigma, Milwaukee, WI). 
Protein concentration was determined using the Bio-Rad protein 
assay kit (Bio-Rad, Hercules, CA), 65 μg protein per sample was 
fractionated on a 10% sodium dodecyl sulfate–polyacrylamide 
gel and transferred to a PVDF membrane (Immobilon, Millipore, 
Bedford, MA). The membranes were blocked in  Tween-20/Tris 
buffered saline and probed with the polyclonal  anti-GATA2 
(H-116, 1:200) and the monoclonal anti-β-actin (C4, sc-47778 
at 1:5000) primary antibodies that recognize both human and 
mouse proteins and with horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse secondary antibodies all from Santa 
Cruz Biotechnology Inc. (Dallas, TX). Antibody staining was 
visualized using the enhanced chemiluminescence detection kit 
(Amersham Pharmacia Biotech, Inc., NJ).
Chromatin Immunoprecipitation 
Methylation of histone-3 (H3) lysine residues were exam-
ined using chromatin immunoprecipitation (ChIP).34 ChIP grade 
antibodies specific for H3 and H3  di-methyl-K9 (H3K9m2) from 
Abcam (Cambridge, MA) and H3  di-methyl-K4 (H3K4m2) 
and tri-methyl-K27 (H3K27m3) from Cell Signaling (Danvers, 
MA) were used to capture protein–DNA complexes. Rabbit and 
mouse IgGs were used for isotype control. The ChIP-DNA was 
quantified by SYBR Green polymerase chain reaction using 
GATA2 promoter specific primers and amplification conditions 
described in Table 1 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A556).
Statistical Analysis
Methylation array data were processed with the 
Methylation Module of GenomeStudio Software using 
HumanMethylation450 manifest v1.1 and after the necessary 
quality check and normalization processes was analyzed as 
described.36 β-values were compared using Fisher’s exact test and 
t test. GATA2 expression between tumor-normal pairs was com-
pared using paired t test. The effects of siRNAs on gene expres-
sion were determined by one-way analysis of variance using 
nonparametric Wilcoxon Rank-sum test to control the impact of 
potential outliers. Tukey’s and Dunnett’s methods were used for 
pair wise and treatment control comparison adjustments, respec-
tively. All analyses were conducted in SAS 9.2.
RESULTS
GATA2 Expression is Markedly 
Reduced in Lung Cancer
Kumar et al.13 indicated that GATA2 expression is key 
for the survival of KRAS mutant lung cancer cells, whereas 
our previous screenings showed epigenetic repression of 
GATA2 in human and mouse lung cancer.26,27 To resolve these 
discrepancies, we first measured GATA2 expression in lung 
tumor-normal pairs and KRAS wild-type and mutant NSCLC 
cell lines. The human GATA2 has three transcript vari-
ants (Var.1, 2, and 3) encoding for two distinct GATA2 pro-
teins, Isoform-1 (encoded by Var.1 and Var.2) and Isoform-2 
(encoded by Var.3; Fig. 1A). TaqMan and SYBR Green 
assays that could discriminate these transcripts showed com-
parable expression of Var.1 and Var.3 in normal lung and to 
a lesser extent in lung tumors and most NSCLC cell lines. 
In contrast, Var.2 was not detected in any of these samples 
(not shown). Evaluation of the total GATA2 transcripts in 24 
lung  tumor-normal pairs revealed 1.3- to 33.6-fold reduced 
expression (p = 2.2 × 10–9) in each tumor (average 8.5-fold) 
compared with the corresponding normal lung (Fig. 1B). Both 
KRAS wild-type (n = 15) and mutant (n = 10) NSCLC cell 
lines also showed comparably reduced expression (Fig. 1C). 
Similarly, NNK-induced lung tumors (n = 6) and derived cell 
lines (n = 5) from A/J mice, respectively, showed fivefold and 
100-fold lower expression compared with normal lung from 
these mice (Fig. 1A,B, Supplemental Digital Content 2, http://
links.lww.com/JTO/A557).
GATA2 Knockdown in Lung Cancer 
Does Not Increase Cell Death
It is plausible that even low-level GATA2 expression 
could play a key survival role in KRAS mutant lung cancer. 
This premise was rigorously tested through transient knock-
down studies in KRAS wild-type (n = 4) and mutant (n = 4) 
NSCLC cell lines. GATA2 expression was reduced by 70% to 
95% in siGATA2-#1 transfected cells compared with the cor-
responding cells transfected with siControl siRNA (Fig. 1D–E). 
However, these further reductions in GATA2 expression did 
not increase cell death in either KRAS wild-type or mutant 
cells (Fig. 1F–G). Furthermore, TaqMan and SYBR Green 
expression assays demonstrated that the KRAS mutant 
NSCLC cell line H441 naturally survives and proliferates 
with barely detectable GATA2 transcripts (ΔCT = 23 [H441] 
versus mean ΔCT = 8 [normal lung]). Among the human and 
mouse NSCLC cell lines evaluated for GATA2 mRNA and 
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protein levels, GATA2 protein was detected by western blot 
only in H1435, a KRAS wt human lung adenocarcinoma cell 
line in which the GATA2 mRNA level was also comparable 
with some normal lung tissues (Fig. 1C, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A557). Transfection of 
this cell line with the siGATA2-#1 and #2 siRNAs resulted in 
65% to 85% reduction in transcription and similarly reduced 
GATA2 protein levels (Fig. 1D, Supplemental Digital Content 
FIGURE 1.  GATA2 expression is significantly reduced in lung cancer and does not provide survival advantage to lung cancer 
cells. (A) A schematic representation of the three transcript variants of GATA2. Expression of total GATA2 in (B) tumor-normal 
pairs and (C) KRAS wild-type and mutant non–small-cell lung cancer (NSCLC) cell lines was compared using a TaqMan assay 
that detects all transcripts. Transient knockdown of GATA2 in KRAS wild-type (D) and mutant (E) NSCLC cell lines does not 
increase cell death (F-G).
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2, http://links.lww.com/JTO/A557) with no difference in cell 
survival from the control cells (Figs. 1D, F). Similarly, reduc-
ing GATA2 expression in KRAS wt and mut human NSCLC 
cell lines by 60% to 85% using a second siRNA targeting a 
different exon (siGATA2-#2) and mouse Gata2 expression by 
50% to 80% in five mouse lung cancer cell lines transfected 
FIGURE 2.  Aberrant methylation of GATA2 is common in lung cancer and occurs early during lung carcinogenesis. (A) 
Combined Bisulfite Modification and Restriction Analysis assay shows GATA2 promoter CpG island is not methylated (poly-
merase chain reaction products are not digested into smaller fragments by BstU1 enzyme) in NHBECs and PBMCs obtained 
from cancer-free donors (top panel), but methylated in most KRAS wild-type and mutant non–small-cell lung cancer (NSCLC) 
cell lines (bottom panel). (B) The degree of methylation across the GATA2 promoter could be estimated based on the propor-
tion of undigested and digested fragments. Top panel: Among the NSCLC cell lines evaluated, GATA2 was not methylated in 
SKMES1 (0%), partially methylated in SW900 (~25%), HCC4006 (~50%), and H1975 (~75%), and completely methylated 
(100%) in H23 and the remaining cell lines as also shown in the bottom panel of (A). Bottom panel: the higher proportion of 
undigested bands in the BstU1+ lanes in the DAC than trichostatin A and Vehicle (Cont) treated KRAS wild-type (H1838) and 
mutant (H358) NSCLC cell lines indicates demethylation of GATA2 by DAC treatment. (C) The Combined Bisulfite Modification 
and Restriction Analysis primers that amplify bisulfite modified GATA2 promoter CpG island regardless of its methylation were 
used as modified DNA specific PCR (ModSP). Methylation Specific PCR assays using primers that specifically amplify only the 
methylated promoter show that GATA2 is unmethylated in NHBECs and HBECs (no band). However, methylation was detected 
in HBEC2 after 12 weeks of exposure to the tobacco carcinogens methylnitrosourea and benzo(a)pyrene-diolepoxide and in 
the transformed HBEC1, 2, and 14 that were exposed to these carcinogens for 12 weeks and further selected for growth in soft 
agar. Quantitative methylation data from HM450K arrays show increased methylation of eight probes located within the GATA2 
promoter CpG island during transformation of (D) HBEC2 and (E) HBEC14. These eight probes were not methylated in normal 
lung but aberrantly hypermethylated in nearly all lung tumors.
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with siGata2 (siGata2-#1 and siGata2-#2) compared with 
siControl transfected cells showed no significant difference in 
cell death (Fig. 2A–F, Supplemental Digital Content 3, http://
links.lww.com/JTO/A558).
GATA2 Methylation Is Highly Prevalent 
and Unique to Human Lung Cancer
The transcription start sites of both human and mouse 
GATA2 are located within CpG islands. The human GATA2 
CpG island was unmethylated in NHBECs and PBMCs 
obtained from cancer-free donors (n = 10), and immortalized 
HBECs (n = 5), but methylated in 30 of 31 (97%) NSCLC 
cells regardless of KRAS mutation status (Table 1, Fig. 2A). 
Similarly, GATA2 was methylated in 159 of 165 (96%) of pri-
mary lung adenocarcinomas regardless of patients’ smoking 
status (Table 1), but unmethylated in distant normal lung (0 
of 10) obtained from a subset of these patients. The different 
levels of GATA2 methylation seen among NSCLC cell lines 
(Fig. 2B, top panel) and levels of demethylation after treatment 
with epigenetic drugs (Fig. 2B, bottom panel) were estimated 
by the semiquantitative methylation assay Combined Bisulfite 
Modification and Restriction Analysis. In contrast, the mouse 
Gata2 CpG island was not methylated in any NNK-induced 
lung tumors, lung cancer cell lines or normal lung tissues 
from the A/J mice (Fig. 3A, Supplemental Digital Content 4, 
http://links.lww.com/JTO/A559).
Quantitative Assays Validate GATA2 
Hypermethylation in Independent Lung Tumors
Genome-wide methylation (HM450K array) was con-
ducted on 56 lung tumors and 21 corresponding normal pairs 
from independent NSCLC cases. Eight probes (depicted by 
arrows in Fig. 1A) within the CpG island extending across 
the transcription start sites of all GATA2 transcripts (CpGi-2) 
were found to discriminate tumors from their corresponding 
normal tissues (Table 2). The average β-value of each probe in 
the 21 normal lung tissues ranged from 0.06 to 0.27 compared 
with 0.32 to 0.52 in the corresponding 56 tumors. On aver-
age, each probe showed 20% to 25% increased methylation in 
the tumors (β-value increase of 0.19–0.26) compared with the 
corresponding normal (Table 2). Because the average β-value 
of each probe was less than or equal to.0.27 in normal lung 
and greater than or equal to 0.32 in the tumors, β greater than 
or equal to 0.30 was used as a cutoff to define hypermethyl-
ation. Based on this cutoff, all eight probes showed very sig-
nificant hypermethylation in tumors compared with normal 
lung (p < 0.0001, Table 2).
HM450K array data generated by TCGA are pub-
licly available at https://tcga-data.nci.nih.gov for 369 lung 
tumors and 74 corresponding normal lung. Evaluation of 
this data for the eight GATA2 probes using the above criteria 
validated that GATA2 methylation is significantly higher in 
lung tumors compared with the corresponding normal lung 
(p < 0.0001, Table 3). Furthermore, the large sample size 
for TCGA data allowed comparison of GATA2 methylation 
TABLE 1.  GATA2 Methylation Status in Normal Tissue and 
Lung Cancer
Sample Number Methylated, n (%)
Cells and cell lines
  NHBECs (cancer-free smokers) 10 0 (0%)
  HBEC cell lines 5 0 (0%)
  PBMC (healthy donors) 10 0 (0%)
  NSCLC cell lines 31 30 (97%)
Primary tissue
  Distant normal lung 10 0 (%)
  Lung adenocarcinoma 165 159 (96%)
  Current smokers 34 31 (91%)
  Former smokers 56 53 (95%)
  Never smokers 75 75 (100%)
NSCLC, non–small-cell lung cancer; PBMC, peripheral blood mononuclear cells.
TABLE 2.  Comparison of Differentially Methylated Probes Within the GATA2 Promoter CpG Island Between Lung Tumor-
normal Pairs From NSCLC Patients
HM450K Probe ID
Normal Lung (N* = 21) NSCLC (N = 56)
p valueM† β-Value M† β-Value
n‡ (%) Mean ± SD Min to Max n (%) Mean ± SD Min to Max Fisher Exact Test t Test
cg00241663 3 (14) 0.26 ± 0.04 0.19–0.35 47 (84) 0.48 ± 0.17 0.14–0.86 2.37E-08 < 0.0001
cg22801992 0 (0) 0.17 ± 0.03 0.12–0.22 35 (63) 0.37 ± 0.16 0.11–0.75 1.69E-07 < 0.0001
cg03839949 4 (19) 0.27 ± 0.03 0.24–0.32 53 (95) 0.50 ± 0.13 0.20–0.81 1.14E-10 < 0.0001
cg22978620 0 (0) 0.06 ± 0.03 0.02–0.12 29 (52) 0.32 ± 0.20 0.02–0.80 8.27E-06 < 0.0001
cg16674492 0 (0) 0.09 ± 0.06 0.02–0.24 32 (57) 0.34 ± 0.25 0.02–0.87 1.03E-06 < 0.0001
cg06490988 0 (0) 0.20 ± 0.07 0.09–0.29 35 (63) 0.38 ± 0.18 0.06–0.76 1.69E-07 < 0.0001
cg19638477 0 (0) 0.15 ± 0.04 0.10–0.23 34 (61) 0.37 ± 0.20 0.08–0.84 2.78E-07 < 0.0001
cg13483882 5 (24) 0.26 ± 0.05 0.13–0.36 50 (89) 0.52 ± 0.16 0.14–0.87 6.72E-08 < 0.0001
* ‘N’ indicates the number of distant normal lung tissue or lung tumor samples from NSCLC patients used.
† The mean β-value for each of the 8 probes was less than 0.3 in normal lung and greater than 0.3 in lung tumors. Thus, β = 0.3 was used as a cutoff to define the prevalence for 
methylation each probes.
‡ ‘n’ indicates the number of samples out of N that show a mean β-value greater than or equal to 0.3 and considered methylated.
NSCLC, non–small-cell lung cancer.
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between adenocarcinoma and squamous cell carcinoma. 
GATA2 hypermethylation was highly prevalent in both of 
these NSCLC subtypes, and the degree of methylation of 
some probes (e.g., cg03839949) showed significant differ-
ences between adenocarcinoma and squamous cell carcinoma 
(Tables 2–4, Supplemental Digital Content 1, http://links.lww.
com/JTO/A556).
Aberrant GATA2 Methylation Occurs 
Early During Lung Carcinogenesis
An in vitro HBEC transformation model that we have 
developed to characterize early premalignancy changes dur-
ing lung carcinogenesis28,29 was used to establish the timing 
of GATA2 methylation. MSP assay revealed that GATA2 was 
unmethylated in HBEC1, 2, and 14 before or during the ini-
tial 8 wks exposure to methylnitrosourea and  benzo(a)pyrene-
diolepoxide (Fig. 2B). However, methylation was detected 
in HBEC2 after 12 wks of exposure and in all three trans-
formed HBEC lines (HBEC-Ts, selected after growth in soft 
agar; Fig. 2C). Comparison of the eight GATA2 probes using 
HM450K array data available for control and transformed 
HBECs showed increased β-values for 7 probes in HBEC2-T 
versus HBEC2, and all 8 probes in HBEC14-T versus 
HBEC14 (Fig. 2D–E, Table 5, Supplemental Digital Content 
1, http://links.lww.com/JTO/A556). Among these probes, 
cg16674492 (dotted arrow in Fig. 1A) interrogated 3 CpGs in 
common with the reverse MSP primer. Concurring with the 
strong MSP signal seen in HBEC2-T, the β-value of this probe 
increased from 0.033 (HBEC2) to 0.408 (HBEC2-T) and from 
0.045 (HBEC14) to 0.167 (HBEC14-T). This indicates a 38% 
(3–41%) and 12% (5–17%) increase in methylation upon 
transformation of HBEC2 and HBEC14, respectively (Table 
5, Supplemental Digital Content 1, http://links.lww.com/JTO/
A556, Fig. 2C–E).
GATA2 Repression Is Epigenetically Mediated
Despite the absence of GATA2 methylation in HBECs 
before transformation (Fig. 2C), its expression in these cells 
is already silenced or significantly reduced (Fig. 1C). The 
responsiveness of GATA2 repression to the histone deacety-
lase inhibitor TSA or the DNA methyltransferases inhibitor 
DAC was investigated in vitro. As shown in Fig. 3A, GATA2 
expression in HBECs was primarily induced by TSA (two- to 
75-fold increase in each HBEC) and to a lesser extent by DAC 
(three- to eightfold increase in two out of four HBECs). In 
contrast, expression of GATA2 in the HBEC-Ts and NSCLC 
cell lines (KRAS wild-type or mutant) was mainly induced by 
DAC (Fig. 3B–D). Overall, DAC treatment increased GATA2 
expression by six- to 21-fold in the HBEC-Ts and two- to 
10-fold in NSCLC cell lines (>100-fold in H441). GATA2 
expression in the primary lung tumors and NSCLC cell lines 
was approximately greated than fivefold lower than in nor-
mal lung tissue (Fig. 1B-C and Fig. 1A, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A557). Thus, reexpres-
sion by greater than or equal to fivefold in DAC/TSA-treated 
NSCLC cell lines compared with vehicle-treated control of 
each cell line suggests restoration of GATA2 expression to 
levels seen in normal lung. Similarly, expression of Gata2 in 
mouse lung cancer cell lines was increased by up to 26- and 
33-fold after TSA or DAC treatments, respectively (Fig. 3B).
Chromatin Remodeling Drives Initial GATA2 
Repression During Lung Carcinogenesis
GATA2 in HBECs was unmethylated and mainly reex-
pressed by TSA, whereas in HBEC-Ts and NSCLC cell 
lines it was methylated and reexpressed the most by DAC. 
This suggests that transcriptional repression of GATA2 pro-
gresses during carcinogen-induced transformation and carci-
nogenesis from the more dynamic chromatin remodeling to 
the more stable repression by adding cytosine-DNA meth-
ylation. This premise was tested by comparing the levels of 
active (H3K4m2) and repressive (H3K9m2 and H3K27m3) 
chromatin marks across the GATA2 promoter using quanti-
tative ChIP assays. HBEC2, HBEC2-wk4 (exposed to meth-
ylnitrosourea and benzo(a)pyrene-diolepoxide for 4 weeks), 
HBEC2-T, and KRAS mutant (Calu-6) and KRAS wild-type 
(H1975) NSCLC cell lines were evaluated. After adjustment 
to total histone-3, the level of H3K9m2 relative to H3K4m2 
TABLE 3.  Comparison of Methylated Probes Within the GATA2 Promoter CpG Island Between Lung Tumor-Normal Pairs From 
NSCLC Patients (The Cancer Genome Atlas data)
HM450K Probe ID
Normal Lung (N = 74) NSCLC (N = 369)
p ValueM β-value M β-value
n (%) Mean ± SD Min to Max n (%) Mean ± SD Min to Max
Fisher Exact 
Test t Test
cg00241663 4 (5) 0.24 ± 0.05 0.15–0.38 310 (84) 0.50 ± 0.19 0.04–0.90 3.75E-40 <0.0001
cg22801992 0 (0) 0.16 ± 0.03 0.10–0.24 238 (65) 0.37 ± 0.17 0.05–0.81 3.02E-29 <0.0001
cg03839949 0 (0) 0.20 ± 0.03 0.13–0.29 319 (86) 0.46 ± 0.14 0.11–0.83 4.66E-51 <0.0001
cg22978620 0 (0) 0.05 ± 0.02 0.02 –0.10 215 (58) 0.33 ± 0.20 0.02–0.85 7.25E-25 <0.0001
cg16674492 0 (0) 0.04 ± 0.02 0.02–0.12 183 (50) 0.30 ± 0.25 0.02–0.88 5.56E-20 <0.0001
cg06490988 0 (0) 0.14 ± 0.04 0.04–0.23 225 (61) 0.36 ± 0.20 0.02–0.82 8.04E-27 <0.0001
cg19638477 0 (0) 0.09 ± 0.03 0.04–0.21 186 (50) 0.31 ± 0.20 0.03–0.91 1.88E-20 <0.0001
cg13483882 3 (4) 0.21 ± 0.05 0.13–0.37 267 (72) 0.45 ± 0.19 0.06–0.88 4.64E-30 <0.0001
NSCLC, non–small-cell lung cancer.
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in HBEC2 was increased by 4-, 21-, 539-, and  338-fold in 
HBEC2-wk4, HBEC2-T, Calu6, and H1975, respectively (Fig. 
3E). Similarly, the level of H3K27m3 relative to H3K4m2 in 
HBEC2 was increased by 20-, 28-, 659-, and 13-fold, respec-
tively (Fig. 3E).
DISCUSSION
The recently described addiction of KRAS mutant lung 
tumors to GATA2 has raised a lot of excitement about the poten-
tial of targeting this most common, but elusive  cancer-driving 
mutation for the treatment of lung cancer.13,41 However, this 
study reports for the first time that GATA2 is often repressed 
in human and murine lung tumors through distinct epigen-
etic mechanisms, and further knock-down of the gene does 
not increase cell death regardless of KRAS mutation status. 
The promoter CpG island of human GATA2 is unmethylated 
in normal lung but aberrantly hypermethylated in nearly all 
primary lung tumors and NSCLC cell lines. After validating 
this highly prevalent hypermethylation in lung cancer using 
publically available large, independent, and quantitative 
methylation data from TCGA, subsequent studies established 
that this epigenetic modification occurs early during tobacco 
carcinogen-induced transformation. In contrast, the mouse 
Gata2 promoter CpG island is unmethylated in NNK-induced 
lung tumors and cancer cell lines despite a dramatic reduc-
tion in expression of the gene compared with normal lung, 
suggesting chromatin-based repression. Most importantly, in 
clear contrast to Kumar et al.,13 our data demonstrated that 
GATA2 is already repressed in both human and murine lung 
cancer and further reducing up to 95% of its expression does 
not increase cell death in KRAS mutant or wild-type lung can-
cer cells. The use of different experimental models in the two 
studies and the fact that Kumar et al.13 did not evaluate epigen-
etic regulation of GATA2, or study primary human tumors or 
normal lung tissue may account for some of the observed dif-
ferences. However, the results from our focused and compre-
hensive studies clearly demonstrate that it is highly unlikely 
that GATA2 suppression will offer any clinical benefit in the 
treatment of KRAS mutant lung cancer.
The normal expression profile of GATA2 in lung tissue 
and its role in lung carcinogenesis is not well characterized. 
Previous studies have shown that the different transcripts of 
GATA2 are expressed in a tissue-specific manner. Transcript 
variant-2 (often described as the IS transcript) is specific 
for hematopoietic and neuronal cells, whereas transcript 
variants-1 and -3 (IG transcripts) are expressed in most tis-
sues.16,42,43 In agreement with those findings, our assays did 
not detect expression of Var.2 in any of the primary lung 
tumor-normal pairs or NSCLC cell lines. In contrast, compa-
rable levels of Var.1 and Var.3 were expressed primarily in the 
normal lung tissue and to a lesser extent in the primary tumors 
and NSCLC cell lines.
Earlier screenings from our group and others have indi-
cated that GATA2 is potentially epigenetically repressed in lung 
cancer. Over a decade ago, Eickhoff et al44. reported that GATA2 
is one of the genes induced by TSA treatment of human lung 
adenocarcinoma cells. Similarly, genome-wide unmasking of 
epigenetically silenced genes in NSCLC cell lines using TSA 
FIGURE 3.  Epigenetic repression of GATA2 in early lung carci-
nogenesis is mediated by chromatin modification and progresses 
to a more stable repression by adding  cytosine-DNA methylation 
upon transformation. (A) GATA2 expression responds better to 
the histone deacetylase inhibitor trichostatin A, while transformed 
HBECs (B), KRAS wild-type (C) and mutant (D) non–small-cell 
lung cancer (NSCLC) cell lines show better response to the 
DNA methyltransferases inhibitor DAC. (E) Chromatin marks for 
transcriptional repression were increased during transformation of 
HBEC2 and the highest repression marks were seen in NSCLC cell 
lines, Calu6 (KRAS mutant) and H1975 (KRAS wild-type).
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and DAC treatments identified GATA2 as one of the repressed 
genes in lung cancer.26 Validating these earlier observations, 
this study first showed that GATA2 methylation is specific to 
tumors (not seen in normal lung tissue and bronchial epithe-
lial cells) and is highly prevalent among NSCLC cell lines 
(97%) and primary lung adenocarcinomas (96%) from cur-
rent, former, and never smokers. These results were validated 
using quantitative methylation analysis of two independent sets 
of NSCLC samples (ours and TCGA). Moreover, the HBEC 
transformation model developed in our laboratory28,29 showed 
that although the GATA2 promoter is unmethylated in HBECs, 
its expression is repressed and primarily reexpressed by TSA 
indicating epigenetic silencing through histone modifications. 
The GATA2 promoter becomes methylated during transforma-
tion and reexpression in the transformed HBECs and NSCLC 
cell lines is mainly induced by DAC indicating the establish-
ment of a more stable repression through promoter CpG island 
hypermethylation. The fact that aberrant methylation of GATA2 
occurs early during transformation also explains its very high 
prevalence in NSCLC cell lines and primary lung tumors.
We previously reported that Gata2 expression is reduced 
in cumene-induced K-ras mutant lung tumors in mice, 
whereas its promoter CpG island remained unmethylated.27 
Similarly, this study shows that Gata2 expression is dramati-
cally reduced in NNK-induced K-ras mutant lung tumors in 
A/J mice and cancer cell lines without methylation of its pro-
moter CpG island. Thus, it appears that epigenetically driven 
silencing of this gene in mice occurs largely by chromatin 
remodeling and does not involve cytosine-DNA methylation 
as seen in human lung tumors. However, irrespective of the 
factors underlying transcriptional repression, further knock-
down of Gata2 in murine K-ras mutant tumors did not affect 
survival of these malignant cells. These conclusive findings 
coupled with identical results in human KRAS wild-type and 
mutant tumor-derived lines do not support GATA2 as a target 
for lung cancer therapy.
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